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Abstract
Introduction: Approximately 26.3 million people in the United States have chronic kidney disease and many more are at risk
of developing the condition. The association between specific metabolic syndrome components and chronic kidney disease
in African American individuals is uncertain.
Methods: Baseline data from 4,933 participants of the Jackson Heart Study were analyzed. Logistic regression models were
used to estimate the odds and 95% confidence intervals of chronic kidney disease associated with individual components,
metabolic syndrome, the number of components, and specific combinations of metabolic syndrome components.
Results: Metabolic syndrome was common with a prevalence of 42.0%. Chronic kidney disease was present in 19.4% of
participants. The prevalence of metabolic components was high: elevated blood pressure (71.8%), abdominal obesity
(65.8%), low fasting high density lipoprotein cholesterol (37.3%), elevated fasting glucose (32.2%) and elevated triglycerides
(16.2%). Elevated blood pressure, triglycerides, fasting blood glucose, and abdominal obesity were significantly associated
with increased odds of chronic kidney disease. Participants with metabolic syndrome had a 2.22-fold (adjusted odds ratio
(AOR) 2.22; 95% CI, 1.78–2.78) increase in the odds of chronic kidney disease compared to participants without metabolic
syndrome. The combination of elevated fasting glucose, elevated triglycerides, and abdominal obesity was associated with
the highest odds for chronic kidney disease (AOR 25.11; 95% CI, 6.94–90.90).
Conclusion: Metabolic syndrome as well as individual or combinations of metabolic syndrome components are
independently associated with chronic kidney disease in African American adults.
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Introduction
Recent studies estimate that approximately 26.3 million people
in the United States have chronic kidney disease (CKD) [1]. There
is a gap in awareness of the condition among high risk adults [2],
particularly minority populations [3]. There are racial differences
in CKD [4]. African American (AA) adults develop CKD at
higher rates than whites, namely during middle age, and
experience a disproportionately greater burden of Stage 5 CKD
[5]. Compared to other racial/ethnic groups, CKD tends to
progress to end stage renal disease (ESRD) more frequently in AAs
[6,7]. The drastic increase in the burden of CKD with regards to
human suffering and economic cost and its link to CVD makes it
an imperative public health issue in the 21
st century [8,9].
Metabolic syndrome (MetS) is the clustering of risk factors for
cardiovascular disease (CVD) and Type 2 diabetes mellitus [10].
PLOS ONE | www.plosone.org 1 July 2014 | Volume 9 | Issue 7 | e101610Components of MetS include abdominal obesity, elevated blood
pressure, plasma triglycerides, fasting blood glucose and low
fasting high-density lipoprotein (HDL) cholesterol [11]. An
association between MetS and CKD has been found in
population-based cohorts and cross-sectional studies [12–15].
Ford et al. (2004) [16] found that the unadjusted prevalence of
MetS increased over time among U.S. adult cohorts, from 23.1%
in the National Health and Nutrition Examination Survey
(NHANES) III (1988–1994) to 26.7% in NHANES 1999–2000,
and 34% in NHANES 2003–2006. Using data from the Jackson
Heart Study (JHS) [17], Taylor and colleagues found that 43.3%
of women and 32.7% of men had MetS [18]. The prevalence of
CKD is higher among Mississippians than among the overall U.S.
population [19] and MetS prevalence in the JHS is among the
highest globally [18,20]. Few studies have examined the associ-
ation between MetS and CKD among minority populations. Here
we report the associations between the presence of MetS,
individual MetS components and CKD. Additionally, we sought
to determine the association between number of MetS compo-
nents and CKD risk, as well as explored combinations of MetS
components and CKD risk among AA adults in JHS.
Methods
Study design and study population
The JHS study is designed to monitor etiology and progression
of CVD prospectively in AAs in Mississippi. JHS population
includes non-institutionalized AAs age 21 years and older in the
Jackson, Mississippi Metropolitan Statistical Area (MSA) counties
(Hinds, Madison, and Rankin) [21]. The final JHS cohort included
5,301 participants from the baseline (Visit 1) examination period
of September 2000 to March 2004. Detailed descriptions of the
study’s design, procedures, recruitment and sample size have been
published elsewhere [21,22]. This study was approved by the
institutional review boards of Jackson State University, Tougaloo
College and the University of Mississippi Medical Center. All of
the participants gave written informed consent.
The baseline examination included a home visit, self-adminis-
tered questionnaires and a clinic visit. During clinical examination
participants were asked about their medication use in the past two
weeks. Participants were asked to fast overnight before the clinical
examination, venous blood was obtained and sitting blood
pressure recorded using standard Hawksley random-zero instru-
ments according to established blood pressure measurement
guidelines [3,23]. Urine samples were obtained according to the
National Committee for Clinical Laboratory Standards [24] and
sociodemographic information was obtained thorough self-admin-
istered questionnaires.
Study variables
CKD was defined as an estimated glomerular filtration rate
(eGFR) of ,60 mL/min/1.73 m
2, or the presence of albuminuria,
or being on dialysis according to the National Kidney Foundation
(NKF) guidelines [25]; coded as ‘‘present’’ and ‘‘absent’’.
Albuminuria was defined as urine albumin to urine creatinine
ratio .30 mg/g based on spot or 24-hour urine values. eGFR was
calculated based on the 4-variable Modification of Diet in Renal
Disease (MDRD) Study equation [GFR=186.0 6 (serum
creatinine)
21.1546(age)
20.2036(0.742 if female) 6(1.210 if African
American)].
MetS was defined according to the Adult Treatment Panel
Third Report (ATP III) [9]; coded as ‘‘yes’’ or ‘‘no.’’ MetS status
was considered positive if the study participant had three or more
of the following: 1) abdominal obesity, defined by a waist
circumference $102 cm in men and $88 cm in women; 2)
elevated blood pressure, defined as a systolic blood pressure of
130 mm Hg or greater and/or a diastolic blood pressure of
85 mm Hg or greater, physician diagnosis, and/or use of
antihypertensive drugs; 3) elevated plasma triglycerides ($
150 mg/dL) or treated dyslipidemia; 4) low fasting HDL
cholesterol (men ,40 mg/dL and women ,50 mg/dL; and 5)
elevated fasting glucose ($100 mg/dL) or use of anti-diabetic
medication.
Statistical analysis
Baseline characteristics were described using means and
standard deviations for continuous variables and counts and
percentages for categorical variables. Comparisons of baseline
characteristics by CKD status (present/absent) were assessed using
t-tests and chi-square tests for continuous and categorical
variables, respectively. MetS status (yes/no), the presence of
individual MetS components, and the number (0 to 5) of MetS
components were determined. Multiple logistic regression models
and 95% confidence intervals were used to estimate the odds of
having CKD that are associated with MetS status, individual MetS
components, and the number of MetS components when age,
gender, education, income, active living index (physical activity
during leisure time excluding sports), body mass index (BMI),
current cigarette smoking, and the use of non-steroidal anti-
inflammatory drugs (NSAIDs) are held constant. Participants with
one, two, three, four, or five MetS components were compared to
those having no MetS components and participants with MetS
were compared to those with fewer than three components of
MetS. The odds ratios of having CKD that are associated with ten
combinations of three components and five combinations of four
components of MetS were assessed and compared with the odd
ratios for participants with zero components to ascertain the
combinations with the highest odds, controlling for covariates.
SAS version 9.3 (SAS Institute, Inc., Cary, North Carolina) was
used to perform all statistical analyses; significance levels were
determined at p,0.05, two tailed.
Results
Characteristics of study participants at baseline
In the current analysis, 368 JHS participants were excluded
because of missing data on CKD. The analytical sample included
4,933 participants from baseline (Exam 1, 2000–2004). The mean
age of participants was 54.9 years (612.8; range, 21–95), and
63.9% were female. A more detailed description of the socio-
demographic characteristics of the sample participants is presented
in Table 1.
MetS, individual MetS components, and CKD
Among study participants, 71.8% had elevated blood pressure;
65.8% were defined as having abdominal obesity; 37.3% had low
fasting HDL cholesterol; 32.2% had elevated fasting glucose; and
16.2% had elevated triglycerides. MetS was common with a
prevalence of 42.0%; the prevalence of CKD was 19.4%.
Comparison of study participants by CKD status
Compared to those without CKD, participants with CKD
were older (mean age 61.1 vs. 52.7 years, p,0.001) and the
proportion of women with CKD was higher compared with
those without (67.7% vs. 62.5%, p=0.02). The percent of
participants who were affluent, married, and reported a high
school education or higher, excellent or good health status, and
drinking alcohol in the past 12 months was significantly lower
Metabolic Syndrome and CKD in African American Adults
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Study participants with CKD had significantly higher mean
BMI, waist circumference, systolic blood pressure, fasting
glucose, fasting total cholesterol, fasting triglycerides (p,0.001),
and fasting low density lipoprotein (LDL) cholesterol (p=0.01)
than those without CKD (Table 2).
Association between individual components of MetS and
CKD
The unadjusted and multivariable-adjusted odds ratios of
having CKD for each individual component of MetS are
presented in Table 3. The adjusted multivariable model shows
that the presence of abdominal obesity, elevated triglycerides,
elevated blood pressure, and elevated fasting glucose were
significantly associated with an increased odds of CKD.
Associations between MetS, the number of MetS
components and CKD
Without adjustment for covariates, participants with MetS
had 3.3-fold higher odds of having CKD than those without
MetS. Age- and gender-adjusted odds ratios indicate that
participants with MetS had 2.68-fold higher odds of having
CKD than those without MetS (p,0.001) (Table 3). Multivar-
iable-adjusted odds ratios show that participants with MetS had
2.22-fold higher odds of having CKD than those without MetS
(p,0.001). Figure 1 shows the prevalence of CKD by the
number of MetS components present; the figure reveals a
significant linear trend between the prevalence of CKD and the
number of MetS components present.
Association between combinations of MetS components
and CKD
Table 4 presents the odds ratios of having CKD for each of the
fifteen specific combinations of MetS components–ten combina-
tions of three components and five combinations of four
components. In multivariable analyses of the ten combinations
of three MetS components, participants with the following three
combinations had the highest odds of having CKD: 1) elevated
fasting glucose, abdominal obesity, and elevated triglycerides (OR
25.11; 95% CI, 6.94–90.90); 2) elevated blood pressure, elevated
triglycerides, and elevated fasting glucose (OR 14.98; 95% CI,
4.59–48.92); 3) low HDL cholesterol, elevated triglycerides, and
elevated fasting glucose (OR 13.92; 95% CI, 3.40–56.98); and 4)
elevated blood pressure, abdominal obesity, and elevated fasting
glucose (OR 13.26; 95% CI, 5.21–33.72). Multivariable analyses
of the five combinations of four MetS components show
participants with the following four combinations had the highest
odds of having CKD: 1) elevated blood pressure, abdominal
obesity, elevated triglycerides, and elevated fasting glucose (OR
27.06; 95% CI, 7.21–101.60); and 2) abdominal obesity, low HDL
cholesterol, elevated triglycerides, and elevated fasting glucose
(OR 18.86; 95% CI, 3.89–91.73).
Discussion
To our knowledge, this investigation is the first to examine the
associations between individual MetS components, the presence of
MetS, the number of MetS components and various combinations
of MetS components and CKD among AAs. The findings reveal
significant relationships between MetS, the presence of individual
MetS components, the number of MetS components and certain
combinations of MetS components, and CKD independent of age,
Table 1. Sociodemographic Characteristics of Jackson Heart Study Participants at Baseline, 2000–2004.
Characteristic N=4,933
n%
Age in years [mean (SD)] 54.9 (12.8)
Female gender 3,154 63.9
Family income
Low
a 642 15.3
Lower-middle
b 1,053 25.1
Upper-middle
c 1,243 29.7
Affluent
d 1,250 29.9
Education level
Less than high school 891 18.1
High school/GED 983 20.0
Vocational school or some college/Associate’s degree 1,428 29.1
Bachelor’s degree or higher 1,612 32.8
Marital status
Married 2,692 54.8
Never been married 610 12.4
Separated 204 4.2
Divorced 744 15.1
Widowed 666 13.6
SD: standard deviation; GED, general educational development.
aLow=# $11,999,
bLower-middle=$12,000–24,999,
cUpper-middle=$25,000–49,999,
dAffluent=$ $50,000.
doi:10.1371/journal.pone.0101610.t001
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smoking, and NSAIDs. These findings are noteworthy because ten
combinations of three MetS components and five combinations of
four components identified are associated with the risk of CKD
among AAs. The findings have important clinical and public
health implications for three reasons: 1) the prevalence of
components of MetS (elevated blood pressure, elevated glucose,
and abdominal obesity) is high in AA populations [18,26], 2) AAs
have a disproportionately higher burden of CKD than white
Americans [27], and 3) the state of Mississippi has a very high
proportion (37%) of AAs in its population. In addition, MetS is
linked with an increased risk of morbidity and mortality for CVD
[28], which is the leading cause of death in Mississippi with death
rates disproportionately higher for AAs than whites and Mis-
sissippi has among the highest CVD death rate nationally [29].
Finally, this investigation contributes to the scarce literature
documenting the relationship between MetS and CKD among
AAs, a population whose risk of CKD progressing to ESRD is
higher than other ethnic groups [7].
Using the ATP III definition for MetS [11], multivariable
models demonstrated that both MetS and individual components
of MetS, with the exception of low HDL cholesterol are
independently associated with increased odds of having CKD in
AA adults. This finding is consistent with a previous investigation
of Korean adults [30] using the ATP III definition. The current
results suggest that among AA adults in Mississippi, MetS
significantly increased the odds of having CKD. The high
prevalence of MetS components, namely elevated blood pressure
and elevated fasting glucose, observed in this population may help
explain these associations. The nonsignificant association between
low HDL cholesterol and CKD may be partly due to the
nonsignificant difference in mean fasting low HDL cholesterol
between those with CKD compared to those without CKD. In
addition, the low prevalence of the component relative to other
components in this population may also contribute to the non-
significance rather than the absence of an association.
Among JHS participants there was a significant positive
association and linear trend between the number of MetS
Table 2. Comparative Analysis of Characteristics of Jackson Heart Study Participants by Chronic Kidney Disease Status at Baseline,
2000–2004.
Characteristics CKD p-value
b
Present Absent
(n=628) (n=2,602)
Age (years) 61.05612.60 52.68612.66 ,.001
Gender (% women) 425 (67.68) 1,625 (62.45) 0.02
Education (% $ high school) 453 (72.60) 2,259 (86.92) ,0.001
Income (% affluent) 109 (21.08) 739 (33.82) ,0.001
Married status (%) 294 (47.04) 1,477 (56.83) ,0.001
Insured (%) 548 (88.10) 2,259 (87.09) 0.49
Health status (% excellent/good) 340 (54.40) 1,936 (74.43) ,0.001
Utilized preventive care (%) 488 (78.21) 1,838 (70.86) ,0.001
Alcohol drinking in past 12 months (%) 205 (32.75) 1,216 (46.86) ,0.001
Current smoker (%) 68 (22.12) 289 (11.17) 0.02
Body mass index (kg/m
2) 33.2667.64 31.4366.91 ,0.001
Active living index
a 1.9260.80 2.1160.79 ,0.001
Type 2 diabetes (% yes) 244 (39.10) 334 (12.86) ,0.001
Waist circumference (cm) 105.5616.67 99.41615.82 ,0.001
Systolic blood pressure (mm Hg) 135.4621.69 124.3616.69 ,0.001
Diastolic blood pressure (mm Hg) 79.05612.09 79.1069.97 0.93
Hypertension (% yes) 549 (87.70) 1,473 (56.70) ,0.001
Fasting blood glucose (mg/dL) 111.10645.13 95.76626.15 ,0.001
Fasting total cholesterol (mg/dL) 205.2645.02 197.2638.68 ,0.001
Fasting low HDL cholesterol (mg/dL) 50.68614.89 50.91613.96 0.72
Fasting LDL cholesterol (mg/dL) 130.7640.38 126.0635.65 0.01
Hypercholesterolemia (% yes) 269 (46.78) 764 (29.90) ,0.001
Fasting triglycerides (mg/dL) 122.4674.74 103.0679.26 ,0.001
Hypertriglyceridemia (%) 64 (12.17) 165 (6.88) ,0.001
NSAIDs use (% yes) 363 (57.80) 1,045 (40.16) ,0.001
CKD, chronic kidney disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; eGFR, estimated glomerural filtration rate; SD, standard deviation; NSAIDs, non-
steroidal anti-inflammatory drugs.
Values are expressed as mean 6SD for continuous variables and percentages for categorical variables.
aActive living index, defined as physical activity during leisure time excluding sports.
bBetween-group comparisons: t test for continuous variables and chi-square for categorical variables.
doi:10.1371/journal.pone.0101610.t002
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consistent with other cross-sectional studies [12,14,30]. This
finding suggests that for AA adults the number of MetS
components present is strongly related to the presence of CKD.
In addition, there was a significant positive linear relationship
between the number of MetS components and the odds of CKD,
which is also consistent with previous cross-sectional studies
[14,30]. The increased risk of CKD associated with a higher
number of MetS components among AA adults highlights the
potential additive detrimental impact [15]. In this study of AA
adults there was not only a high prevalence of individual
components of MetS, but also a high clustering of components,
which could place this population at a higher risk of CKD.
Among the possible combinations of three MetS components,
the combination of abdominal obesity, elevated triglycerides, and
elevated fasting glucose was associated with the highest odds of
CKD. Among the possible combinations of four MetS compo-
nents, the combination of elevated blood pressure, elevated fasting
glucose, elevated triglycerides and abdominal obesity was associ-
ated with the highest odds of CKD. Notably, abdominal obesity,
elevated fasting glucose, and elevated triglycerides were in both of
the combinations that had the highest odds for CKD. Of the
combinations of three components, the three groups with the
highest odds for CKD all included elevated fasting glucose.
Similarly, of the combinations of four components, elevated fasting
glucose was in three with the highest odds of CKD. Thus, in the
focal population combinations of elevated fasting glucose and
other MetS components seem to have an additive impact on the
odds of CKD. This pattern highlights the impact of diabetes on
the risk of CKD among AA adults. The significant relationships
between certain combinations of MetS components and CKD
observed in this population suggest the relative importance of these
specific combinations. The relatively high prevalence of key MetS
components in this population may partially explain these
associations. Further studies are needed to explore this relation-
ship, particularly among AAs.
One of the objectives of the Healthy People 2020 report is to
reduce the proportion of the U.S. adult population with CKD by:
1) reducing the proportion of persons with CKD who have
elevated lipids levels and blood pressure, and 2) increasing the
proportion of persons with diabetes and CKD who receive
medical evaluations [31]. In addition, the National Kidney
Foundation Kidney Disease Outcomes Quality Initiative (NKF
KDOQI) guidelines recommend screening individuals with
diabetes and hypertension for undetected kidney disease during
regular clinical visits because studies have shown that in
individuals with diabetes and hypertension, keeping blood sugar
and blood pressure under control prevented or delayed the onset
of kidney disease [25,32]. Identifying individuals with CKD in its
initial stage and informing them of their condition will help these
individuals live a healthy lifestyle and may prevent the progression
to ESRD. However, awareness of CKD among JHS participants is
reportedly low [3]. Similarly, among this population the treatment
of CKD was fairly low (52%) compared to other chronic diseases
Table 3. Unadjusted and Multivariable-adjusted Odds of Having Chronic Kidney Disease for each Individual Component, Number
of Components of Metabolic Syndrome and Metabolic Syndrome among Jackson Heart Study Participants at Baseline, 2000–2004.
Variable Odds ratio of chronic kidney disease (95% CI)
Unadjusted
OR (95% CI) p-value
b
Age-gender- adjusted
OR (95% CI) p-value
b
Multivariable adjusted
a
OR (95% CI) p-value
b
Abdominal obesity 2.17 (1.77–2.67) ,0.001 2.01 (1.61–2.51) ,0.001 1.41 (1.06–1.89) 0.020
Elevated triglycerides 2.11 (1.68–2.65) ,0.001 1.88 (1.48–2.39) ,0.001 1.74 (1.33–2.28) ,0.001
Low HDL cholesterol 1.19 (0.99–1.43) 0.070 1.31 (1.08–1.59) 0.007 1.20 (0.96–1.50) 0.110
Elevated blood pressure 6.06 (4.45–8.26) ,0.001 4.03 (2.93–5.55) ,0.001 4.41 (2.99–6.49) ,0.001
Elevated fasting glucose 3.22 (2.69–3.85) ,0.001 2.41 (1.99–2.90) ,0.001 1.99 (1.60–2.47) ,0.001
0 components Reference Reference Reference
1 component 2.72 (1.48–4.97) 0.001 1.96 (1.06–3.62) 0.03 2.57 (1.20–5.51) 0.020
2 components 4.40 (2.46–7.88) ,0.001 3.03 (1.68–5.47) ,0.001 3.64 (1.72–7.72) 0.001
3 components 9.27 (5.22–16.47) ,0.001 5.64 (3.14–10.14) ,0.001 5.85 (2.75–12.46) ,0.001
4 components 11.23 (6.18–20.43) ,0.001 6.74 (3.66–12.40) ,0.001 6.82 (3.12–14.89) ,0.001
5 components 14.70 (7.43–29.08) ,0.001 8.59 (4.28–17.22) ,0.001 9.89 (4.17–23.49) ,0.001
Metabolic syndrome
c 3.31 (2.76–3.97) ,0.001 2.68 (2.22–3.24) ,0.001 2.22 (1.78–2.78) ,0.001
OR, odds ratio; CI, confidence interval; HDL, high density lipoprotein.
aAdjusted for age, gender, education, income, active living index, body mass index (BMI), cigarette smoking, and non-steroidal anti-inflammatory drugs (NSAIDs).
bP-values calculated using logistic regression.
cCompared to those with ,3 components of metabolic syndrome.
doi:10.1371/journal.pone.0101610.t003
Figure 1. Prevalence of Chronic Kidney Disease by Number of
Metabolic Syndrome Components among African American
Adults, Jackson Heart Study, 2000–2004. Linear trend, P,0.001.
doi:10.1371/journal.pone.0101610.g001
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Shuval and colleagues (2011) [33] demonstrated that among AAs,
vigorous physical activity was associated with the absence of MetS;
this relationship is of great importance given the high level of
physical inactivity (36.0%) among Mississippi adults and the high
prevalence of MetS observed in among JHS participants (42.0%).
In the 2011 Mississippi Behavior Risk Factor Surveillance System
(BRFSS), AA male adults were more likely to smoke (33.3%) than
white male adults (28.9%) (34) in addition, compared to white
adult Mississippians, AAs adults were more likely to report having
hypertension and diabetes, were less likely to have their cholesterol
checked, and reported higher rates of obesity [34]. These
disproportionate rates of poor health behaviors and outcomes
among AA adults may explain the high prevalence of MetS and
CKD observed in the JHS.
The analyses in this investigation revealed significant relation-
ships between individual, combinations of MetS components and
CKD as well as the overall presence of MetS in a high-risk
population. Focused screening of AA adults using key MetS
components may help prevent the onset of CKD, increase
awareness of the condition, and alleviate the burden and
associated healthcare costs in this high-risk population. Under-
standing the way in which specific combinations of MetS
components are associated with the risk of CKD will facilitate
the creation of focused interventions, treatments, and evidenced-
based CKD screening strategies, especially among high-risk
populations.
This study has many strengths including: use of a large,
heterogeneous sample of AAs; standard phenotypically character-
ization; and more highly educated than participants in statistical
metropolitan areas with similar multi-ethnic studies of CVD, thus
making this sample more comparable to similar European
American populations in similar metropolitan areas. However, it
also has several potential limitations. First, because the analyses
use cross-sectional data, causal relationships between MetS and
CKD cannot be inferred from the results. Second, the focal cohort
is AA adults and thus the findings are limited to this adult
population [35]. Third, in this cohort GFR was not measured
directly, and eGFR were calculated using the MDRD formula,
which may not provide an accurate estimation of GFR in AA
populations. In addition, the equation was developed among
diseased patients and has not been validated in a general
population, although the formula is used extensively in clinical
practice for the assessment of renal injury [3,30]. Lastly, the JHS
sample was limited to non-institutionalized adults and was not
designed to be a nationally representative sample. Given the
sampling frame of the JHS cohort, findings from the study might
not be generalized to all AAs.
We report that MetS is common in a heterogeneous population-
based cohort of AA adults. Individual components of MetS, the
Table 4. Unadjusted and Multivariable-adjusted Odds of Having Chronic Kidney Disease for Specific Combinations of among
Jackson Heart Study Participants at Baseline, 2000–2004.
10 and 5 Combinations of 3 and 4 Components of Metabolic Syndrome, Respectively
Variable Odds ratio of chronic kidney disease (95% CI)
Unadjusted
OR (95% CI) p-value
b
Age-gender- adjusted
OR (95% CI) p-value
b
Multivariable adjusted
a
OR (95% CI) p-value
b
No components Reference Reference Reference
EBP+AO+LHDL (n=947) 9.59 (5.12–17.95) ,0.001 6.47 (3.38–12.41) ,0.001 6.11 (2.41–15.50) ,0.001
EBP+AO+TRG (n=457) 13.90 (7.28–26.56) ,0.001 9.67 (4.83–19.37) ,0.001 10.32 (3.51–30.31) ,0.001
EBP+AO+FBG (n=1130) 14.61 (7.85–27.19) ,0.001 10.09 (5.24–19.43) ,0.001 13.26 (5.21–33.72) ,0.001
EBP+LHDL+TRG (n=343) 10.57 (5.43–20.56) ,0.001 7.31 (3.56–15.05) ,0.001 6.02 (2.02–17.89) 0.001
EBP+LHDL+FBG (n=514) 11.62 (6.09–22.18) ,0.001 8.51 (4.22–17.15) ,0.001 9.44 (3.35–26.57) ,0.001
EBP+TRG+FBG (n=290) 18.21 (9.34–35.53) ,0.001 14.13 (6.66–29.97) ,0.001 14.98 (4.59–48.92) ,0.001
AO+LHDL+TRG (n=337) 10.14 (5.21–19.74) ,0.001 6.84 (3.39–13.80) ,0.001 5.09 (1.65–15.73) 0.005
AO+LHDL+FBG (n=543) 11.03 (5.78–21.03) ,0.001 8.70 (4.34–17.45) ,0.001 10.01 (3.46–28.96) ,0.001
AO+TRG+FBG (n=276) 19.55 (9.99–38.27) ,0.001 16.59 (7.82–35.19) ,0.001 25.11 (6.94–90.90) ,0.001
LHDL+TRG+FBG (n=202) 13.85 (6.89–27.85) ,0.001 11.92 (5.28–26.89) ,0.001 13.92 (3.40–56.98) ,0.001
EBP+AO+LHDL+TRG (n=280) 12.11 (6.16–23.81) ,0.001 8.28 (3.97–17.25) ,0.001 6.71 (2.01–22.33) 0.002
EBP+LHDL+TRG+FBG (n=183) 14.37 (7.08–29.16) ,0.001 11.69 (5.11–26.76) ,0.001 15.01 (3.58–62.90) ,0.001
EBP+AO+TRG+FBG (n=249) 21.31 (10.81–42.02) ,0.001 16.43 (7.64–35.32) ,0.001 27.06 (7.21–101.60) ,0.001
BP+AO+HDL+FBG (n=456) 11.96 (6.23–22.84) ,0.001 9.08 (4.47–18.46) ,0.001 11.68 (3.93–34.70) ,0.001
AO+LHDL+TRG+FBG (n=178) 15.03 97.38–30.63) ,0.001 12.87 (5.61–29.52) ,0.001 18.86 (3.89–91.73) ,0.001
OR, odds ratio; CI, confidence interval; HDL, high density lipoprotein.
AO, abdominal obesity; TRG, elevated triglycerides; EBP, elevated blood pressure; FBG, elevated fasting glucose; LHDL, Low high-density lipoprotein.
aAdjusted for age, gender, education, income, active living index, body mass index (BMI), cigarette smoking, and non-steroidal anti-inflammatory drugs (NSAIDs).
bP-values calculated using logistic regression.
abdominal obesity, defined by a waist circumference $102 cm in men and $88 cm in women; elevated blood pressure, defined as a systolic blood pressure of 130 mm
Hg or greater and/or a diastolic blood pressure of 85 mm Hg or greater, physician diagnosis, and/or use of antihypertensive drugs; elevated plasma triglycerides ($
150 mg/dL) or treated dyslipidemia; low fasting HDL cholesterol (men ,40 mg/dL and women ,50 mg/dL; and elevated fasting glucose ($100 mg/dL) or use of anti-
diabetic medication.
Metabolic syndrome defined as having three or more of the following: abdominal obesity, elevated blood pressure, fasting blood glucose, triglycerides and low HDL
cholesterol.
doi:10.1371/journal.pone.0101610.t004
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components are independently associated with increased odds of
CKD. Key specific combinations of MetS components were
associated with higher odds of CKD, and the risk of CKD
increased progressively as more MetS components were present.
These current findings highlight the need for targeted prevention,
screening, health promotion, and treatment intervention efforts
related to MetS components among AA adults; a focus on the
MetS components associated with the greatest increases in the risk
of CKD should be a significant part of these efforts. Additional
studies focused on AAs or other racial/ethnic groups should
further investigate if treatment of the different combinations of
MetS components modifies the risk of the development and
progression of CKD.
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